hereditary angioedema
CSL Behring’s angioedema treatments receives NICE recommendation
September 26, 2025Regulatory Affairs, Research and Development Andembry, CSL Behring, hereditary angioedema
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending CSL Behring’s ANDEMBRY (garadacimab) for …
CSL Behring’s therapy for hereditary angioedema receives positive assessment in Germany
June 26, 2025Market Access, Market Research, Medical Communications, Research and Development, Sales and Marketing CSL Behring, Institute for Quality and Efficiency in Health Care, Rare Diseases, clinical trials, hereditary angioedema, market access
CSL Behring has announced a key milestone for its hereditary angioedema (HAE) therapy, garadacimab, following a positive benefit assessment by …
Shire to acquire Dyax in $5.9 billion deal
November 2, 2015Manufacturing and Production, Research and Development, Sales and Marketing Dyax, M&A, MA, R&D, Shire, hereditary angioedema, rare disease
Shire has struck a deal to acquire the biotech firm Dyax for $5.9 billion, in order to acquire exclusive rights …
